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Abstract
Background: Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal disorder and
the evidence for efficacy of most drug therapies in the treatment of IBS is weak. A popular
alternative is probiotics, which have been used in several conditions. including IBS. Probiotics are
live microbial food supplements.
The aim of this systematic review and meta-analysis of randomized trials study was to evaluate the
efficacy of probiotics in alleviating symptoms in patients with irritable bowel syndrome. We
searched Ovid versions of MEDLINE (1950–2007), EMBASE (1980–2007), CINAHL (1982–2007),
AMED (1985–2007), the Cochrane library and hand searched retrieved papers.
Results: We identified 14 randomized placebo controlled trials. Combined data suggested a
modest improvement in overall symptoms after several weeks of treatment: for dichotomous data
from seven trials the overall Odds Ratio (OR) was 1.6 (95% CI, 1.2 to 2.2); for continuous data
from six trials the standardised mean difference (SMD) was 0.23 (95% CI, 0.07 to 0.38).
For individual symptoms the results differed between the pooled dichotomous and pooled
continuous data. Trials varied in relation to the length of treatment (4–26 weeks), dose, organisms
and strengths of probiotics used.
Conclusion: Probiotics may have a role in alleviating some of the symptoms of IBS, a condition
for which currently evidence of efficacy of drug therapies is weak. However, as IBS is a condition
that is chronic and usually intermittent longer term trials are recommended. Such research should
focus on the type, optimal dose of probiotics and the subgroups of patients who are likely to benefit
the most.
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Background
Irritable Bowel Syndrome (IBS) is a common chronic gas-
trointestinal disorder, characterized by abdominal pain,
bowel dysfunction and bloating in the absence of struc-
tural abnormality [1]. In the West, about 15% of the pop-
ulation is affected at some time during their life, and it is
more common in females [2]. IBS is also recognized in
children [3]. The burden of illness associated with IBS is
considerable. A UK study [4,5] found that IBS sufferers
reported substantially lower quality of life scores (as
measured by the SF36 health survey questionnaire). They
had more time off work and used healthcare more often.
IBS accounts for 12% of visits to primary care physicians
and 28% of visits to gastroenterologists [6,7].
Patients with IBS may be classified by their predominant
bowel habit: diarrhoea-predominant IBS, constipation-
predominant IBS, or IBS with alternating bowel move-
ments [8]. Diagnostic criteria such as Manning, Rome I, II
and III have proved useful for research purposes by ensur-
ing homogeneity of patient populations, though their
applicability in clinical practice is limited and they are sel-
dom used [1].
The evidence for efficacy of most drug therapies in the
treatment of IBS is weak [9]. A popular alternative is pro-
biotics, which have been used in several conditions
[10,11] including IBS. Probiotics are live microbial food
supplements. Examples include lactic acid bacteria and
bifidobacteria which are widely used in yogurts and other
dairy products. They retain viability during storage and
survive passage through the stomach and small bowel
[12]. The colonic microflora normally presents a barrier to
invading organisms. However, when the integrity of the
microbiota is impaired through illness, stress, antibiotics
treatment, physiological alterations in the gut, or change
in diet, pathogens may become established [12]. Bifido-
bactetrium resist the colonization of pathogens in the
large bowel [13]. We aimed to assess whether probiotics
alleviated symptoms in patients with IBS.
Methods
Literature search
We searched Ovid versions of MEDLINE (1950–2007),
EMBASE (1980–2007), CINAHL (1982–2007), AMED
(1985–20007), as well as the Cochrane Database of Sys-
tematic Reviews and Cochrane Controlled Trials Register,
Cochrane Library issue 3, 2007 (search date August 2007).
MESH terms used were 'PROBIOTICS' and 'COLONIC
DISEASE', 'FUNCTIONAL' or 'IRRITABLE BOWEL SYN-
DROME'. Further terms were included as text words. A
high sensitivity "therapy" (trials) filter was applied to the
EMBASE search. No other limits were applied to any of the
searches. All registers on Current Controlled Trials http://
www.controlled-trials were searched to locate ongoing
studies and, where possible, lead researchers were con-
tacted for further details. In addition, we hand searched
the reference lists of retrieved full-text papers.
Selection
We included randomised controlled trials that compared
the effects of any probiotic therapy (regardless of type,
dose and duration of treatment) with placebo in patients
with IBS. Studies were included only if the two groups
were treated equally except for the provision of the probi-
otic to one group. Studies not adhering to this were
excluded. For example, in Bittner's study [14] a two week
randomised placebo control trial patients in the interven-
tion group received a pro-biotic plus a pre-biotic. We
included studies of adults and children with IBS consist-
ent with Manning or Rome diagnostic criteria, which has
recently been updated to Rome III [15].
The primary outcome measure was improvement in over-
all symptoms as defined by the presence or absence of the
following physical symptoms: pain, flatulence, bloating,
anxiety and quality of life. As a number of studies
included symptoms of flatulence this was included in the
analysis.
Secondary outcome measures were the following individ-
ual symptoms: pain, flatulence, bloating, anxiety and
quality of life. Two reviewers independently assessed arti-
cles and abstracts and each put forward articles for inclu-
sion. Non English language publications were excluded.
Data abstraction
The review was carried out in accordance with the recom-
mendations of the QUOROM statement [16]. Two
reviewers independently assessed trial methodological
quality and extracted data. Disagreements were resolved
by discussion. All studies were assessed for methodologi-
cal quality in four specific areas: method of randomisa-
tion, clear allocation concealment, blinding and use of
intention to treat analysis. Total scores were given for each
study included in the review, with maximum score of
four. Data was also extracted on the number of partici-
pants, age range, diagnostic criteria used for IBS, study
subgroups, the type and dose of probiotics, length of treat-
ment and the relevant outcome measures used in the
study. Study authors were contacted for missing or incom-
plete information.
Data analysis
Review Manager Version 4.3.1 was used for the statistics
analysis and odds ratio (OR) and 95% confidence interval
(CIs) as summary statistics were calculated. A fixed-effects
model with Mantzel-Haenzel method was used to calcu-
late the pooled OR. For continuous outcomes reported on
non-standard scales, standardized mean difference (SMD)BMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
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were used. For studies with more than one intervention
arm a conservative estimate (i.e. the intervention with the
least effect) was used. Heterogeneity was examined with I2
statistics and where important heterogeneity existed rea-
sons for this were explored. Publication bias was exam-
ined by a funnel plot. A sensitivity analysis was carried out
by excluding studies of lower quality (scores less than
four) and subgroup analysis was undertaken for adults
only and children only. Due to limited data, it was not
possible to carry out a subgroup analysis for type of pro-
biotics.
Results
We identified 497 citations, 178 of which were duplicate
records and were therefore excluded. Two authors
screened 319 abstracts and identified potentially relevant
articles. Twenty two retrieved articles were independently
reviewed for inclusion and exclusion criteria. The review-
ers were not masked to any aspect of the studies (e.g. jour-
nal type, author's names etc). On further analysis of
retrieved articles, 8 trials were excluded for being non-
controlled studies. Therefore, a total of 14 articles met the
inclusion criteria [17-30] (figure. 1). As a number of stud-
ies included symptoms of flatulence this was included in
the analysis. For example, in Gade's study [18] published
in 1989, the IBS definition of constipation and/or diar-
rhoea, abdominal pain, meteorism, borborygmus and
flatulence was used.
Trials were from USA (three), Poland (two), Ireland
(two), UK (one) France (one), Israel (one), Finland (one),
Italy (one), Sweden (one) and Denmark (one). One trial
included women only [30]; the remainder included
female and male participants with the majority being
women (table 1). Two studies included children [17,19],
though Bausserman's study [17] included an age range of
6–20 years. Trials varied in relation to the type, dose and
strengths of probiotic(s) used. Number of probiotics var-
ied from one to multiple, e.g. VSL#3 (contains 8 different
bacterial strains). Three studies included more than one
arm in the intervention group[27,29,30] (table 1).
In six studies the length of treatment was four weeks, in
three studies eight weeks, in two studies six weeks and in
two studies six months (table 1). One study was a cross
over of 20 weeks (two weeks wash in and washout) [28].
Diagnostic criteria for IBS used were as follows: ten trials
used Rome II, two trials used Rome, and one trial used
Manning. However, in Gade's study [18] published in
1989, the IBS definition of constipation and/or diarrhoea,
abdominal pain, meteorism, borborygmus and flatulence
was used. One study included constipation predominant
Flow chart for search results Figure 1
Flow chart for search results.B
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Table 1: Study characteristics
First author Number of participants (age 
range)l
Diagnostic criteria Probiotics* Measured outcomes included: Length of treatment
Guyonnet, 2007, France 274
(20–65)
Rome II
Constipation-
Predominant IBS
Activia Danone, Combination containing 
Bifidobacterium. animalis DN 
1730101(1.25 × 1010 cfu per pot) together 
with S. thermophilus and L. bulgaricus 
1.2 × 109 cfu per pot
Health related quality of life 
Bloating, abdominal pain, global 
digestive symptom
6 weeks
Gawronska A, 2007, Poland 37
(6–16)
Rome II LGG (Lactobacillus rhamnosus GG) 
3 × 109 cfu, twice daily,
Self reported abdominal pain 4 weeks
Whorwell PJ, 2006, UK 362
(19–69)
All female
Rome II 3 different strengths treatments
Bifidobacterium (B.) infantis 35624 × 106 
live bacterial cells
B. infantis 35624 × 108 live bacterial cells
B. infantis 35624 × 1010 live bacterial cells
Once daily capsule
Global assessment (SGA) of IBS 
symptoms
Abdominal pain/discomfort, 
Bloating/distension, passage of gas
4 weeks
Bausserman M, 2005, USA 64
(6–20)
Rome II lactobacillus GG 1010 and Inulin was also 
present both in treatment and in placebo 
one capsule twice a day
Changes in abdominal pain severity 6 weeks
Niv, 2005, Israel 54
(19–70)
Rome II 1 × 108 cfu of Lactobacillus reuteri ATCC 
55730, four tablets to be taken for seven 
days, followed by a dose of 2 tablets per 
day until close of the study
abdominal pain, quality of life 6 months
Kajander K, 2005, Finland 103
(21–65)
Rome I and Rome II Combination
Lactobacillusrhamnosus GG, Lactobacillus 
rhamnosus LC 705, Bifidobacterium breve 
Bb 99 and Propionibacterium 
freudenreichii ssp. Shemanii JS 8–9 × 109
Abdominal pain, distension, 
flatulence, borborygmi
6 months
Kim HJ, Vazquez Roque M, 2005, 
USA
48
(21–75)
Rome II VSL # 3 mixture of bacteria combination 
twice daily 
(450 billion viable lyophilized bacteria)
One packet twice a day
Abdominal bloating, flatulence, 
abdominal pain
8 weeks
O'Mahony L, 2005, Ireland 80
(18–73)l
Rome II Either B infantis 35624 Or L. salivarIus 
UCC 4331 each delivered in a dose of 
1 × 10 10
Once Daily
Abdominal pain or discomfort, 
bloating or distension and bowel 
movement difficulty
Quality of life assessment using an 
IBS specific questionnaire
8 weeks
Saggioro A, 2004, Italy Unclear (6–64) Rome II Combination L. plantarum LP01 plus one 
strain of B. breve BR0
5 × 10 10 cfu/ml once a day
Combination Strain of L. plantarum LP01 
plus a strain of L. acidophilus LA02 one 
strain of B. breve BR0
5 × 109 cfu/ml once a day
Pain score at different locations in 
RLQ and LLQ of the abdomen
Overall symptom score
4 weeks
Kim HJ, Camilleri M, 2003, USA 25
(19–70)
Rome II
Diarrhea predominant symptom
Combination VSL # 3 mixture of 
bacteria
One packet twice a day
abdominal pain, bloating, flatulence 8 weeks
Niedzielin K, 2001, Poland 40
(27–63)
Manning Lactobacillus plantarum 299V
5 × 107 CFU/ml twice a day
improvement in pain and flatulence 4 weeks
Nobaek S, 2000, Sweden 60
(21–78)
Rome 400 ml/day of rose hip drink syrup 
containing 5 × 10 7 cfu/ml of L. plantarum 
DSM 9843 (strain 299V) and 0.009 g/ml 
oat flour
Overall GI function abdominal pain, 
flatulence, defecation
4 weeks
O'Sullivan MA, 2000, Ireland 24
(24–60)
Rome Lactobacillus GG 1 × 1010 cfu/day
two tablets twice a day
Abdominal bloating, pain, bowel 
frequency
20 week
Gade, 1989, Denmark 54
(16–60)
constipation and or diarrheoa, 
abdominal pain, meteorism, 
borborygmus and flatulence
Paraghurt (freeze dried culture of 
Streptococcus faecium) 4 tablets morning 
and evening
abdominal pain, meteorism, 
borborygmus, flatulence
4 weeks
cfu: Colony Forming Unit
Combination denotes a mixture of probioticsBMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
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Table 2: Assessment of methodological quality of randomised trials:
Paper Nobaek
2000
O Sullivan
2000
Niedzelin
2001
Kim
2003
Saggioro
2004
Kajander
2006
O' 
mahoney
2005
Gawronska
2007
Bausserman
2005
Whorwell
2006
Niv
2005
Kim
2005
Guyonnet
2007
Gade
1989
Randomiz
ation
-- - - -++ + + - - - + * +
Concealm
ent of 
Allocation
-+ - - -++ + + -- - + * +
Double 
Blinding
++ - + -+ + + + + + + + * +
Intention 
to treat
-+ + + +- + + - + + + + +
Total 1 3 1 2 1 3 4 4 3 2 2 2 4* 4
+ Clear reporting of the methodological quality
- Not clear from the paper
* Clarified after emailing author
Forest plot of improvement in overall symptoms (dichotomous data) in patients with IBS treated with probiotics compared to  placebo Figure 2
Forest plot of improvement in overall symptoms (dichotomous data) in patients with IBS treated with probi-
otics compared to placebo.BMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
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IBS [20]; one included diarrhea-predominant symptom
[22].
Measured outcomes varied, from overall gastrointestinal
(GI) function to individual symptoms such as abdominal
pain, flatulence and bloating. Four studies included qual-
ity of life using different questionnaires: Kajander et al
[21] used RAND 36 item health survey [31] Guyonnet et
al [20] used FDDQL questionnaire [32]. Whorwell [30]
and O'Mahony [27] used IBS specific quality of life ques-
tionnaire [33].
Assessment of quality of studies
Methodological qualities varied (Table 2), with seven
studies scoring two or less and four studies scoring a max-
imum of four.
Overall improvement
Combined data suggested a modest improvement in over-
all symptoms after several weeks of treatment: for dichot-
omous data from seven trials [18-22,24,30] (895
participants) (figure 2) the overall Odds Ratio (OR) was
1.6 (95% CI, 1.2 to 2.2); heterogeneity I2 = 28%. For con-
tinuous data from six trials (657 participants) [20-
22,26,27,30], the standardised mean difference (SMD)
was 0.23 (95% CI, 0.07 to 0.38), I2 = 0% (figure 3).
In the six trials [18,20-22,24,30] of adults only (850 par-
ticipants) the overall improvement in symptoms
remained statistically significant, OR 1.59 (95% CI, 1.19
to 2.13), I2 = 35%. Results for overall improvement in
symptoms were stable to sensitivity analysis [18-20]; (365
participants), OR 1.62 (95% CI, 1.06 to 2.48), I2 = 20%.
Abdominal pain
Seven trials [17-19,21,24,26,28] (398 participants)
reported a statistically significant improvement in
abdominal pain, OR 2.88 (95% CI, 1.84 to 4.50), I2 =
24% (figure 4).
In five studies of adults only [18,21,24,26,28] (297 partic-
ipants) the effect remained statistically significant, OR
3.34 (95% CI, 1.99 to 5.61), I2 = 1%.
Two studies of children [17,19] (101 participants)
reported on improvement in abdominal pain. However,
high heterogeneity (I2  = 63%) suggested pooling was
inappropriate. In Bausserman's study [17] (64 partici-
pants), Lactobacillus GG (LGG) was not superior to pla-
cebo in relieving abdominal pain. There were no
differences in other gastrointestinal symptoms, except for
a lower incidence of perceived abdominal distension (P =
0.02 favouring LGG). In Gawroska's study [19] (37 partic-
Forest plot of improvement in overall symptoms (continuous data) in patients with IBS treated with probiotics compared to  placebo Figure 3
Forest plot of improvement in overall symptoms (continuous data) in patients with IBS treated with probiot-
ics compared to placebo.BMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
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ipants), those in the LGG group were more likely to have
treatment success (defined as no pain based on face pain
scales) than those in the placebo group and had reduced
frequency of pain (P = 0.02), but not severity of pain.
Using continuous data in nine trials [17,19-23,26,27,30]
(792 participants) there was no statistically significant
improvement in abdominal pain, SMD 0.05; (95% CI, -
0.09 to 0.19), I2 = 51%. The heterogeneity was high. The
most likely reason for this was the use of different scales
in different studies; some used Likert scales ranging from
0 to 6 whereas others used visual analogue scales or face
pain scales.
Flatulence
Five studies [18,21,22,24,26] (274 participants) reported
a significant improvement in symptoms of flatulence, OR
2.31 (95%CI, 1.37 to 3.9), I2 = 7% (figure 5). Using con-
tinuous data in five studies [21-23,26,30] (388 partici-
pants), there was no statistically significant improvement
in symptoms of flatulence, SMD 0.11; (95% CI, -0.09 to
0.31), I2 = 49%. The high heterogeneity was most likely to
be due to use of different scales in different studies.
Bloating
Four studies [18,21,23,28] (253 participants) reported a
statistically significant improvement in symptoms of
bloating, OR 1.75 (95% CI, 1.03 to 2.96), I2 = 0% (figure
6).
Using continuous data in six studies [20-23,27,30] (653
participants), there was no statistically significant differ-
ence in symptoms of bloating, SMD 0.05 (95% CI, – 0.10
to 0.21), I2 = 8%.
Quality of Life
Four trials aimed to report quality of life (QoL) but inad-
equate data prevented pooling of the results. In a study by
O'Mahony et al [27] QoL was assessed by administration
of an IBS specific questionnaire. They reported that for
most domains, QoL scores were numerically lower than
those for placebo for the patients randomized to the pro-
biotics, but reached statistical significance versus placebo,
during the treatment phase only, for health worry for bifi-
dobacterium (at the 0.05 level) and dysphoria for lactoba-
cillus at the 0.10 level. In Kajander's Study [21] the RAND
36 items health survey was used. They report that at base-
Forest plot of improvement of abdominal pain (dichotomous data) in patients with IBS treated with probiotics compared to  placebo Figure 4
Forest plot of improvement of abdominal pain (dichotomous data) in patients with IBS treated with probiotics 
compared to placebo.BMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
Page 8 of 11
(page number not for citation purposes)
line the mean QoL was somewhat higher in the probiotic
group, but the difference between the groups was non sig-
nificant compared with the baseline. There was no change
in the mean score at three months or six months in either
group.
Whorwell et al [30] used the IBS specific QoL question-
naire and the Hospital Anxiety and Depression Scale
(HAD). No significant change in the QoL or HAD scores
was reported with any of the probiotic dosages in compar-
ison to placebo.
In a study by Guyonnet et al [20], health related QoL was
assessed by the administration of the Functional Digestive
Disorders Quality of Life questionnaire. They reported
that the global score did not differ significantly between
the probiotic group and the control group.
Adverse effects
Nine trials reported that there were no adverse effects with
probiotics [17-19,21-24,26,28], four trials reported
adverse effects [20,25,27,30] and one study [29] reported
no data.
In the Niv study [25] (54 participants), the following
adverse events were reported in the probiotic group: dys-
pepsia (one), headache (one) and nausea (none) and in
the control group: dyspepsia (three), headache (none)
and nausea (one). The differences were not significant. In
the Whorwell study [30] (362 participants), 17 of subjects
withdrew because of an adverse event. There was no sig-
nificant difference between the groups and there were no
details on the characteristics of adverse events. In
O'Mahony's study [27] (80 participants), four subjects
reported adverse events during the study. In Guyonnet's
study [20], (274 participants) 23 subjects (ten from the
control group and 13 from the probiotic group) reported
minor adverse events. Four in the control group and three
in the probiotic group stopped the product after an
adverse event. No further details were given on the nature
of these events.
Discussion
In patients with IBS, probiotics showed a modest
improvement in overall symptoms, using both dichoto-
mous and continuous data. However, it is interesting to
note that neither of the two studies [20,30] which contrib-
uted most of the weight in the analysis, were statistically
significant. It is likely that the two Bifidobacterium strains
used in these two studies may have been ineffective. Based
on average control event rates the Numbers Needed to
Treat is estimated to be between 9 and 21 to have 1 patient
Forest plot of improvement of flatulence (dichotomous data) in patients with IBS treated with probiotics compared to placebo Figure 5
Forest plot of improvement of flatulence (dichotomous data) in patients with IBS treated with probiotics com-
pared to placebo.BMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
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improve. By removing studies with quality scores less than
four, the results remained stable to sensitivity analysis.
For individual symptoms the results differed between the
pooled dichotomous and pooled continuous data. Using
dichotomous data probiotics also improved symptoms of
abdominal pain, flatulence and bloating. However using
continuous data, the improvement in these symptoms
were not statistically significant. One study used a cross-
over design [28]. The data presented allowed us to include
it for dichotomous outcomes (bloating and abdominal
pain). Excluding this study did not affect the findings for
abdominal pain, but rendered the effect on bloating non-
statistically significant. The heterogeneity was also high
for symptoms of abdominal pain and flatulence. This is
likely to be due to use of different scales in different stud-
ies.
Other therapies for IBS include antispasmodics, antidiar-
rhoeal agents, laxatives and antidepressants [1], but over-
all the evidence for efficacy of these existing drug therapies
for IBS is weak [9]. Probiotics have been used previously
in different conditions [10,11]. On entering the gastroin-
testinal tract, probiotics are unaffected by acid, bile salts
and proteolytic enzymes. In the small bowel they multiply
and live on the surface of epithelial cells. Their main ben-
eficial effect is to act as a barrier to harmful organisms by
adherence and production of substances that have an anti-
biotic effect, as well as stimulating immune processes in
the host [11]. In the colon they have a major role of fer-
menting undigested carbohydrates and soluble dietary
fibre, producing short-chain fatty acids [11]. Probiotics
may change the flora, effecting the fermentation process,
so less gases are produced that may cause symptoms, or
they may interfere with the growth or harmful effect of
producing diarrhoea, or they may stimulate the immune
process to prevent some unidentified antigen response
[34].
As there were inconsistencies in the reporting of adverse
events, it was not possible to adequately estimate the fre-
quency of the adverse events. However, nine studies
reported that there were no adverse events. Clearer report-
ing of adverse events in future studies would be helpful. In
addition, a review of probiotics in Crohn's Disease found
they were generally well tolerated and few side effects were
reported. The reported side effects included bloating, diar-
rhoea, constipation, nausea and epigastric pain [35].
Occasionally probiotics can cause infections in immuno-
compromised individuals [36,37].
One of the limitations of this review is exclusion of non-
English language publications which may lead to an over-
representation of positive studies. Other limitations
Forest plot of improvement of bloating (dichotomous data) in patients with IBS treated with probiotics compared to placebo Figure 6
Forest plot of improvement of bloating (dichotomous data) in patients with IBS treated with probiotics com-
pared to placebo.BMC Gastroenterology 2009, 9:15 http://www.biomedcentral.com/1471-230X/9/15
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include the clinical and statistical heterogeneity between
studies. For example, the age and gender of the study pop-
ulations varied as did the length of follow up and dosage
and type of probiotics used. There was also variation in
the definition of overall symptoms in different studies:
two studies included only subcategories of the IBS popu-
lation (constipation – [20] or diarrhea-predominant par-
ticipants [22]. Studies varied in relation to the length of
treatment, number, type, dosage and strengths of probi-
otic(s) used. Whilst some studies used one probiotic, oth-
ers used a combination e.g. VSL#3 which contains a
cocktail of 8 different bacterial strains. In three studies
more than one treatment arm was used [27,29,30]. Whor-
well et al [30] studied a probiotic (B. infantis 35624) at
three different strengths of 106, 108, 1010 against placebo.
The study found B. infantis 35624 at a dosage level of 108
cfu is effective in reducing the symptoms of IBS at four
weeks. They suggested that this may be because the high-
est dose formulation 1 × 1010 cfu, "coagulated" into a firm
glue like mass. As Whorwell's study had more than one
intervention arm, in our meta-analysis a conservative esti-
mate (i.e. the intervention with the least effect) was used.
The majority of trials [11] lasted eight weeks or less. This
is important in a condition that is chronic and usually
intermittent. Therefore, longer term studies would be
more helpful. In some trials, we could not include data as
they were incomplete or missing despite writing to
authors. Specifically, trials should report individual out-
comes for IBS. These should include important symptoms
such as urgency and difficult defecation. We could not
carry out subgroup analysis based on sex and probiotics
used. Problems due to different scales used occurred for
reporting of continuous outcomes. For instance, some
studies used Likert scales ranging from 0 to 6 whereas oth-
ers used visual analogue scales and face pain scales. The
use of different scales may explain high heterogeneity
observed in pooling of continuous data for abdominal
pain and flatulence. High heterogeneity, due to small
number of participants, may also have occurred in the
case of subgroup analysis of children. As the number of
studies was small it was difficult to draw conclusions on
publication bias. For overall assessment with the largest
number of studies (seven studies), only one study with
negative result was reported, raising the possibility that
small studies with negative findings may not have reached
publication. Finally, in this review flatulence was included
despite not strictly being part of the IBS criteria. This was
due to a number of early studies including flatulence as a
symptom [18]. Our meta-analysis was carried out before
the publication of a study by Kajander et al [38] published
in 2008. This randomized placebo controlled trial using
multispecies probiotic further strengthens our findings.
Conclusion
Probiotics may have a role in alleviating some of the
symptoms of IBS, a condition for which currently evi-
dence of efficacy of drug therapies is weak. Longer term
trials are recommended as IBS is a condition that is
chronic and usually intermittent. However, further
research should focus on the type, optimal dose of probi-
otics and the subgroups of patients who are likely to ben-
efit the most.
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